Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
PBYILOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 5, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 11,250 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awa
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
PBYI(NASDAQ:PBYI) LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that on September 2, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 25,750 shares of Puma common stock to four new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity a
Puma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment Conference
PBYI(NASDAQ:PBYI) LOS ANGELES--(BUSINESS WIRE)--On 9/8/25, Puma Biotechnology CEO and President Alan Auerbach will present a company overview at the H.C. Wainwright Global Investment Conference.
CORRECTION: Puma Biotechnology Sees Q2 Sales $50.000M-$53.000M vs $52.75M Est
PBYICORRECTION: Puma Biotechnology Affirms FY2025 Sales Guidance of $212.00M-$222.00M vs $217.80M Est
PBYIPuma Biotechnology Lowers FY2025 Sales Guidance from $212.00M-$222.00M to $192.00M-$198.00M vs $217.80M Est
PBYIPuma Biotechnology Sees Q2 Sales $48.000M-$50.000M vs $52.75M Est
PBYIPuma Biotechnology Q1 Adj. EPS $0.10 Beats $(0.02) Estimate, Sales $46.00M Beat $44.55M Estimate
PBYIPuma Biotechnology And Er-Kim Sign Distribution Agreement For NERLYNX In Breast Cancer Patients; Er-Kim Will Be Distribution Partner For NERLYNX In Eastern Europe And Central Asia
PBYIHC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $7 Price Target
PBYIPuma Biotechnology Sees Q1 Sales $42.500M-$45.500M vs $47.50M Est
PBYIPuma Biotechnology Sees FY2025 Sales $212.000M-$222.000M vs $207.90M Est
PBYIPuma Biotechnology Q4 Adj EPS $0.43 Beats $0.10 Estimate, Sales $59.10M Beat $52.50M Estimate
PBYIHC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $7 Price Target
PBYIPuma Biotechnology's NERLYNX Added To NCCN Guidelines For HER2-Mutated Cervical Cancer; Approved As Second-Line Therapy For Recurrent Or Metastatic Disease Based On Phase II SUMMIT Trial Results
PBYIHC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $7 Price Target
PBYIPuma Biotechnology Initiates ALISCA™-Breast1 Phase II Trial Of Alisertib In Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
PBYIHC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $7 Price Target
PBYIPuma Biotechnology Announced Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022
PBYI